Page 158 - rcv31n3.vp

Prevención cardiovascular en el diabético Revista Uruguaya de Cardiología
Washington Vignolo, Bernardo Layerle Volumen 31 | nº 3 | Diciembre 2016

2 diabetes and raised excretion of urinary albumin: tension. 2010 Feb;55(2):399-407.
randomised, double blind, placebo controlled trial doi:10.1161/HYPERTENSIONAHA.109.139816.
(the DIABHYCAR study). BMJ. 2004 Feb
84. Gu Q, Burt VL, Dillon CF, Yoon S. Trends in an-
28;328(7438):495.
tihypertensive medication use and blood pressure
doi:10.1136/bmj.37970.629537.0D.
control among United States adults with hyperten-
75. Daly CA, Fox KM, Remme WJ, Bertrand ME, sion: The National Health and Nutrition Examina-
Ferrari R, Simoons ML, et al. The effect of perin- tion Survey, 2001 to 2010. Circulation. 2012 Oct
dopril on cardiovascular morbidity and mortality in 23;126(17):2105-14.
patients with diabetes in the EUROPA study: results http://dx.doi.org/10.1161/CIRCULATIONAHA.112.
from the PERSUADE substudy. Eur Heart J. 2005 096156.
Jul;26(14):1369-78. doi:10.1093/eurheartj/ehi225.
85. Belsey JD. Optimizing adherence in hypertension:
76. ONTARGET Investigators. Telmisartan, rami- a comparison of outcomes and costs using single ta-
pril, or both in patients at high risk for vascular blet regimens vs individual component regimens. J
events. N Engl J Med. 2008 Apr 10;358(15):1547-59. Med Econ. 2012;15(5):897-905.
doi:10.1056/NEJMoa0801317. doi:10.3111/13696998.2012.689792.
77. Telmisartan Randomised AssessmeNt Study 86. Clark CE, Taylor RS, Shore AC, Ukoumunne
in ACE iNtolerant subjects with cardiovascu- OC, Campbell JL. Association of a difference in
lar Disease (TRANSCEND) Investigators. systolic blood pressure between arms with vascular
Effects of the angiotensin-receptor blocker telmisar- disease and mortality: a systematic review and
tan on cardiovascular events in high-risk patients in- meta-analysis. Lancet. 2012 Jan
tolerant to angiotensin-converting enzyme inhibi- 30;379(9819):905-14.
tors: a randomised controlled trial. Lancet. 2008 Sep doi: 10.1016/S0140-6736(11)61710-8.
28;372(9644):1174-83.
doi:10.1016/S0140-6736(08)61242-8. 87. Catapano AL, Graham I, De Backer G, Wiklund
O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS
78. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff Guidelines for the management of dyslipidaemias.
SL, Gifford N, Schrier RW. The effect of nisoldipi- Eur Heart J. 2016 Aug:ehw272. doi:10.1093/eur-
ne as compared with enalapril on cardiovascular out- heartj/ehw272.
comes in patients with non-insulin-dependent diabe-
tes and hypertension. N Engl J Med. 1998 Mar5;338 88. Adiels M, Olofsson S-O, Taskinen M-R, Borén
(10):645-52. doi:10.1056/NEJM199803053381003. J. Overproduction of very low-density lipoproteins is
the hallmark of the dyslipidemia in the metabolic
79. Sleight P, Redon J, Verdecchia P, Mancia G, syndrome. Arterioscler Thromb Vasc Biol. 2008
Gao P, Fagard R, et al. Prognostic value of blood Jul;28(7):1225-36.
pressure in patients with high vascular risk in the doi:10.1161/ATVBAHA.107.160192.
Ongoing Telmisartan Alone and in combination with
Ramipril Global Endpoint Trial study. J Hypertens. 89. Colhoun HM, Betteridge DJ, Durrington PN,
2009 Jul;27(7):1360-9. Hitman GA, Neil HAW, Livingstone SJ, et al.
doi:10.1097/HJH.0b013e32832d7370. Primary prevention of cardiovascular disease with
atorvastatin in type 2 diabetes in the Collaborative
80. Wald DS, Law M, Morris JK, Bestwick JP, Wald
Atorvastatin Diabetes Study (CARDS): multicentre
NJ. Combination therapy versus monotherapy in re-
randomised placebo-controlled trial. Lancet. 2004
ducing blood pressure: meta-analysis on 11,000 par-
Aug 21;364(9435):685-96.
ticipants from 42 trials. Am J Med. 2009
doi:10.1016/S0140-6736(04)16895-5.
Mar;122(3):290-300.
doi:10.1016/j.amjmed.2008.09.038. 90. Sever PS, Dahlof B, Poulter NR, Wedel H, Bee-
vers G, Caulfield M, et al. Prevention of coronary
81. Mancia G, Fagard R, Narkiewicz K, Redon J,
and stroke events with atorvastatin in hypertensive
Zanchetti A, Böhm M, et al. 2013 ESH/ESC guide-
patients who have average or lower-than-average
lines for the management of arterial hypertension.
cholesterol concentrations, in the Anglo-Scandina-
Eur Heart J. 2013 Jul;34(28):2159-219.
vian Cardiac Outcomes Trial—Lipid Lowering Arm
doi:10.1093/eurheartj/eht151.
(ASCOT-LLA): a multicentre randomised controlled
82. Hermida RC, Ayala DE, Mojón A, Fernández trial. Lancet. 2003 Apr 5;361(9364):1149-58.
JR. Influence of time of day of blood pressure-lowe- doi:10.1016/S0140-6736(03)12948-0.
ring treatment on cardiovascular risk in hypertensi-
91. Sever PS, Poulter NR, Dahlöf B, Wedel H, Co-
ve patients with type 2 diabetes. Diabetes Care. 2011
llins R, Beevers G, et al. Reduction in cardiovascu-
Jun;34(6):1270-6. doi:10.2337/dc11-0297.
lar events with atorvastatin in 2,532 patients with
83. Gupta AK, Arshad S, Poulter NR. Compliance, type 2 diabetes: Anglo-Scandinavian Cardiac Outco-
safety, and effectiveness of fixed-dose combinations mes Trial—lipid-lowering arm (ASCOT-LLA). Dia-
of antihypertensive agents: A meta-analysis. Hyper- betes Care. 2005 May [citado 2016 Oct
502